Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation

We report on a case of metastatic urothelial bladder carcinoma (mUBC) treated with anlotinib combined with sintilimab. A 69-year-old male was diagnosed with non-muscle invasive bladder cancer (NMIBC). He received transurethral resection of bladder tumor (TURBT) and intravesical gemcitabine chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jian-zhou, Wu, Wei, Pan, Jin-feng, Wang, Hong-wei, Jiang, Jun-hui, Ma, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180869/
https://www.ncbi.nlm.nih.gov/pubmed/34109111
http://dx.doi.org/10.3389/fonc.2021.643413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180869/
https://www.ncbi.nlm.nih.gov/pubmed/34109111
http://dx.doi.org/10.3389/fonc.2021.643413

Ejemplares similares